Iker Mauleon-Ausejo

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters.

Journal: Human gene therapy
Published: August 29, 2025

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas.

Journal: Cell reports. Medicine
Published: October 08, 2024

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

Journal: Neuro-oncology
Published: March 30, 2024

The rise of TIM-3: A promising immune target in diffuse midline gliomas.

The rise of TIM-3: A promising immune target in diffuse midline gliomas.

Journal: Clinical and translational medicine
Published: December 20, 2023

Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry.

Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry.

Journal: STAR protocols
Published: October 31, 2023

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.

Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models.

Journal: JCI insight
Published: August 29, 2023

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.

Journal: Cancer cell
Published: February 07, 2023

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma.

Journal: Molecular therapy oncolytics
Published: April 04, 2022

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas.

Journal: JCI insight
Published: September 14, 2021

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.

Journal: Molecular cancer therapeutics
Published: June 29, 2021
Showing 1-10 of 10

Last Updated: 09/26/2026